Founded in February 2003, PluroGen Therapeutics can be a start-up pharmaceutical firm that's while developing a topical antimicrobial gel (TAG) to prevent and treat burn and skin-ulcer infections. Instead of most new pharmaceutical compounds without any clinical history, TAG was used by thousands of patients inside a large college hospital within the last 10 years. Using the favorable clinical response, the two founding doctors desire to start a company making the drug available to the greater medical community. Despite the fact that the doctors are recognized government physiques inside the section of wound care and holders of numerous patents, neither has extensive business experience. PluroGen is presently seeking $1.5 million in financing from angel traders to initiate the drug-approval process and subsequently expects to find $6.5 million in funding in the proper partner to complete Phase III tests and gain final approval within the U.S. Food and drug administration. Students are asked for to evaluate whether TAG will attract enough being of curiosity to experienced traders and, if that is the case, the number of equity traders would demand as a swap for your $1.5 million. Because of the presumed future funding having a proper partner, the angel traders must carefully weigh the outcomes in the next round of financing round the terms they are demanding now.
Estimated Submission On |